Kailera Therapeutics, Inc. (KLRA) Stock

About Kailera Therapeutics, Inc.

Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.

Kailera Therapeutics, Inc. is headquartered in US.

Kailera Therapeutics, Inc. (KLRA) stock trades at $18.66 with a market capitalization of $2.42B. The stock is valued at a price-to-earnings (P/E) ratio of -14.81, price-to-book of -6.17, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $16.39 and $28.23, and currently trades 33.9% below its 52-week high.

On profitability, Kailera Therapeutics, Inc. generates a return on equity (ROE) of 41.79% — well above the market average, a sign of a high-quality business, return on capital employed of -24.52%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.kailera.com